Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Subjects with Advanced Solid Malignant Tumors (Daiichi Pharmaceutical Corporation #U13565-A-U101).

Trial Profile

Phase 1, Open Label Study to Assess the Safety and Tolerability of U3-1565 in Subjects with Advanced Solid Malignant Tumors (Daiichi Pharmaceutical Corporation #U13565-A-U101).

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs U3 1565 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top